Key result
LEPR Gln223Arg polymorphism shows no association with hypertension prevalence in urban adults.
Why the study?
Despite advances in understanding CAD in the general population, much of the variance in disease development remains unexplained, and genetics may contribute significantly, especially in premature CAD and pediatric cancer survivors.
Cross-Sectional (n=470)
Relative Risk: 0.95 (95% CI 0.7–1.27)
Absolute Event Rate: 43.8% vs 40.8%
p-value: p=0.76
LEPR Gln223Arg shows no hypertension link after adjustment; leaves open other genetic factors in premature CAD for cancer survivors.
As pediatric cancer survivors age, long-term cardiovascular complications related to chemotherapeutic toxicities, as well as development of premature coronary artery disease (CAD) from radiation and increased prevalence of CAD risk factors such as obesity, are likely to become more prevalent. Despite advances in our understanding of CAD in the general population, a large amount of the variance in development of disease is unexplained. Given the strong heritability of CAD, some of this may be attributable to genetics. Premature CAD in particular segregates in families, and twin studies have shown that the genetic contribution is greater in premature CAD. In this article, we present a brief review of the literature on the genetics of CAD. Over 30 monogenic disorders feature CAD phenotypes. Recently, however, interest has shifted to understanding the genetic variation contributing to common, complex disease, where disease risk is polygenic and characterized by environmental factors, and gene-environment interactions. CAD epitomizes such a disease, and highlights the inherent difficulties in understanding the underlying genetic architecture of such diseases. Long-term cardiovascular complications in patients who survive pediatric cancers result in significant morbidity and mortality in this population. Clinicians need to be aware of screening and treatment strategies for primary and secondary prevention of cardiovascular complications in this group. Further research is necessary to define the epidemiology and risk factors of premature CAD in survivors of pediatric cancers, and to determine whether candidate genes for cardiovascular disease in the general population are also susceptibility genes in this vulnerable population.
No takes yet. Share an insight, caveat, or question.
Svati Hasmukh Shah (2007) conducted a cross-sectional in Hypertension (n=470). LEPR Gln223Arg polymorphism vs. GG genotype was evaluated on Prevalence of hypertension (PR 0.95, 95% CI 0.70-1.27, p=0.76).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: